NASDAQ:CALA

Calithera Biosciences - CALA Stock Forecast, Price & News

$3.06

-0.08 (-2.55%)

(As of 10/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.95
▼
$3.20
50-Day Range: $2.78
▼
$4.88
52-Week Range: $2.30
▼
$43.00

Volume: 69,592 shs
Average Volume: 128,709 shs
Market Capitalization: $14.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.67

Calithera Biosciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 510.0% Upside
$18.67 Price Target
Short Interest: Healthy
2.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.11
Upright™ Environmental Score
News Sentiment: -0.99
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($7.33) to ($4.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

611th out of 1,075 stocks

Pharmaceutical Preparations Industry

284th out of 537 stocks

3.4

Analyst's Opinion

Consensus Rating
Calithera Biosciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.67, Calithera Biosciences has a forecasted upside of 510.0% from its current price of $3.06.
Amount of Analyst Coverage
Calithera Biosciences has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.79% of the float of Calithera Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Calithera Biosciences has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Calithera Biosciences has recently increased by 6.10%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Calithera Biosciences does not currently pay a dividend.
Dividend Growth
Calithera Biosciences does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Calithera Biosciences has received a 68.66% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Calithera Biosciences is -1.11.

0.6

News and Social Media Coverage

News Sentiment
Calithera Biosciences has a news sentiment score of -0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Calithera Biosciences this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for CALA on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Calithera Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.60% of the stock of Calithera Biosciences is held by insiders.
Percentage Held by Institutions
53.65% of the stock of Calithera Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Calithera Biosciences are expected to grow in the coming year, from ($7.33) to ($4.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Calithera Biosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Calithera Biosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Calithera Biosciences has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Calithera Biosciences (NASDAQ:CALA) Stock

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Receive CALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CALA Stock News Headlines

October 3, 2022 | marketwatch.com

Calithera Biosciences Gets FDA Fast Track For Lung Cancer Drug

October 3, 2022 | nasdaq.com

Calithera Gets FDA Fast Track Designation For Sapanisertib For Squamous Lung Cancer Treatment

October 3, 2022 | finance.yahoo.com

Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer

October 3, 2022 | finance.yahoo.com

Calithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidate

October 1, 2022 | seekingalpha.com

CALA Calithera Biosciences, Inc.

September 21, 2022 | reuters.com

Calithera Biosciences Inc

September 17, 2022 | finance.yahoo.com

3 Penny Stocks With Surprisingly Superior Fundamentals

September 6, 2022 | finance.yahoo.com

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 16, 2022 | finance.yahoo.com

Companies Like Calithera Biosciences (NASDAQ:CALA) Could Be Quite Risky

August 16, 2022 | finance.yahoo.com

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

August 16, 2022 | seekingalpha.com

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2022 Results - Earnings Call Transcript

August 12, 2022 | msn.com

Earnings Preview For Calithera Biosciences

August 8, 2022 | finance.yahoo.com

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

July 13, 2022 | apnews.com

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

July 13, 2022 | finance.yahoo.com

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

July 6, 2022 | tmcnet.com

Calithera Biosciences Announces First Patient Enrolled in Phase

July 6, 2022 | finance.yahoo.com

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer

July 5, 2022 | finance.yahoo.com

What is a Reverse Stock Split and How Does it Work?

June 23, 2022 | benzinga.com

Calithera Commences Mid-Stage Study Of DLBCL Candidate

June 23, 2022 | finance.yahoo.com

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma

June 15, 2022 | finanznachrichten.de

Calithera Biosciences, Inc.: Calithera Biosciences Announces 1-for-20 Reverse Stock Split

June 14, 2022 | seekingalpha.com

Calithera Biosciences announces 1-for-20 reverse stock split to regain listing compliance

June 14, 2022 | finance.yahoo.com

Calithera Biosciences Announces 1-for-20 Reverse Stock Split

May 27, 2022 | finance.yahoo.com

After a record-breaking decade, biotech is discovering what hard times feel like

May 17, 2022 | finance.yahoo.com

Calithera to Present at the H.C. Wainwright Global Investment Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CALA Company Calendar

Last Earnings: 8/15/2022
Today: 10/07/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CALA
CUSIP: N/A
CIK: 1496671
Web: www.calithera.com
Phone: (650) 870-1000
Fax: N/A
Employees: 92
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.67
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +510.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($26.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-115,090,000.00
Net Margins: N/A
Pretax Margin: -1,530.22%
Return on Equity: -226.50%
Return on Assets: -83.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.81
Quick Ratio: 4.81

Sales & Book Value

Annual Sales: $9.75 million
Price / Sales: 1.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.17 per share
Price / Book: 1.41

Miscellaneous

Outstanding Shares: 4,865,000
Free Float: 4,544,000
Market Cap: $14.89 million
Optionable: Optionable
Beta: 1.76

Key Executives

Dr. Susan M. Molineaux Ph.D. (Age 68)
Founder, CEO, Pres & Director
Comp: $923.21k

Ms. Stephanie Wong (Age 48)
CFO & Sec.
Comp: $616.4k

Dr. Eric B. Sjogren (Age 65)
Sr. VP of Drug Discovery
Comp: $579.13k

Dr. Christopher J. Molineaux Ph.D. (Age 69)
Sr. VP of Devel.

Mr. Frank Parlati Ph.D. (Age 53)
Sr. VP of Research

Dr. Emil T. Kuriakose M.D. (Age 42)
Chief Medical Officer

Dr. Susan B. Demo Ph.D.
Sr. VP of R&D Operations

Dr. Allison Dillon Ph.D.
Sr. VP of Commercial & Portfolio Strategy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CALA Stock - Frequently Asked Questions

Should I buy or sell Calithera Biosciences stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CALA shares.
View CALA analyst ratings or view top-rated stocks.
What is Calithera Biosciences' stock price forecast for 2022?: 4 brokerages have issued 1-year price targets for Calithera Biosciences' stock. Their CALA share price forecasts range from $8.00 to $30.00. On average, they anticipate the company's share price to reach $18.67 in the next twelve months. This suggests a possible upside of 510.0% from the stock's current price.
View analysts price targets for CALA or view top-rated stocks among Wall Street analysts.
How have CALA shares performed in 2022?: Calithera Biosciences' stock was trading at $13.30 at the beginning of the year. Since then, CALA stock has decreased by 77.0% and is now trading at $3.06.
View the best growth stocks for 2022 here.
When is Calithera Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CALA earnings forecast.
How were Calithera Biosciences' earnings last quarter?: Calithera Biosciences, Inc. (NASDAQ:CALA) released its earnings results on Monday, August, 15th. The biotechnology company reported ($1.59) earnings per share for the quarter, topping analysts' consensus estimates of ($2.70) by $1.11.

When did Calithera Biosciences' stock split?: Calithera Biosciences shares reverse split before market open on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Calithera Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).
What is Calithera Biosciences' stock symbol?: Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."
How do I buy shares of Calithera Biosciences?: Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Calithera Biosciences' stock price today?: One share of CALA stock can currently be purchased for approximately $3.06.
How much money does Calithera Biosciences make?: Calithera Biosciences (NASDAQ:CALA) has a market capitalization of $14.89 million and generates $9.75 million in revenue each year. The biotechnology company earns $-115,090,000.00 in net income (profit) each year or ($26.59) on an earnings per share basis.
How can I contact Calithera Biosciences?: Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.calithera.com. The biotechnology company can be reached via phone at (650) 870-1000 or via email at ir@calithera.com.

This page (NASDAQ:CALA) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Calithera Biosciences - CALA Stock Forecast, Price & News

Calithera Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability